|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 89.34 | 104.64 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1740.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 40.90 | 31.13 | 24.19 | 17.54 | 6.54 | CEPS(Rs) | 50.27 | 40.60 | 34.15 | 27.43 | 15.80 | DPS(Rs) | 12.00 | 9.60 | 7.20 | 4.00 | 2.40 | Book NAV/Share(Rs) | 186.00 | 154.66 | 130.88 | 106.77 | 97.05 | Tax Rate(%) | 26.22 | 29.64 | 25.35 | 20.41 | 28.17 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 18.66 | 18.18 | 16.87 | 14.57 | 9.34 | EBIT Margin(%) | 16.73 | 15.55 | 13.20 | 9.54 | 5.40 | Pre Tax Margin(%) | 16.53 | 15.26 | 12.77 | 8.87 | 4.08 | PAT Margin (%) | 12.19 | 10.74 | 9.53 | 7.06 | 2.93 | Cash Profit Margin (%) | 14.98 | 14.00 | 13.46 | 11.03 | 7.09 | Performance Ratios | | | | | | ROA(%) | 17.71 | 15.89 | 14.00 | 11.25 | 4.07 | ROE(%) | 24.01 | 21.80 | 20.36 | 17.21 | 6.86 | ROCE(%) | 32.92 | 31.46 | 27.27 | 20.35 | 9.81 | Asset Turnover(x) | 1.45 | 1.48 | 1.47 | 1.59 | 1.39 | Sales/Fixed Asset(x) | 2.73 | 2.61 | 2.37 | 2.44 | 2.35 | Working Capital/Sales(x) | 3.44 | 3.78 | 4.36 | 9.52 | 19.12 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.37 | 0.38 | 0.42 | 0.41 | 0.42 | Receivable days | 23.17 | 34.41 | 52.52 | 45.38 | 53.01 | Inventory Days | 58.57 | 53.79 | 45.64 | 38.91 | 46.92 | Payable days | 128.38 | 132.94 | 138.23 | 106.09 | 135.21 | Valuation Parameters | | | | | | PER(x) | 17.01 | 17.98 | 16.00 | 9.72 | 37.90 | PCE(x) | 13.84 | 13.78 | 11.34 | 6.21 | 15.68 | Price/Book(x) | 3.74 | 3.62 | 2.96 | 1.60 | 2.55 | Yield(%) | 1.72 | 1.72 | 1.86 | 2.35 | 0.97 | EV/Net Sales(x) | 2.13 | 1.94 | 1.54 | 0.78 | 1.35 | EV/Core EBITDA(x) | 10.10 | 9.48 | 8.36 | 4.80 | 12.64 | EV/EBIT(x) | 11.78 | 11.48 | 10.85 | 7.46 | 22.37 | EV/CE(x) | 2.61 | 2.48 | 1.98 | 1.55 | 2.26 | M Cap / Sales | 2.24 | 2.10 | 1.65 | 0.75 | 1.24 | Growth Ratio | | | | | | Net Sales Growth(%) | 16.51 | 13.11 | 3.61 | 13.75 | -4.01 | Core EBITDA Growth(%) | 20.04 | 25.61 | 17.98 | 72.84 | -10.63 | EBIT Growth(%) | 24.47 | 34.69 | 41.21 | 96.94 | -20.61 | PAT Growth(%) | 31.39 | 28.70 | 37.88 | 168.36 | -19.63 | EPS Growth(%) | 31.39 | 28.70 | 37.88 | 168.36 | -19.63 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.00 | 0.00 | 0.01 | 0.07 | 0.23 | Current Ratio(x) | 2.57 | 2.58 | 2.21 | 1.52 | 1.25 | Quick Ratio(x) | 1.64 | 1.55 | 1.47 | 0.96 | 0.72 | Interest Cover(x) | 80.72 | 52.89 | 30.93 | 14.21 | 4.10 | Total Debt/Mcap(x) | 0.00 | 0.00 | 0.00 | 0.04 | 0.09 |
|
|
|
|
|
|